Month: November 2023

In the peer reviewed publication, the International Journal of Plant Biology, Cibus provides two case studies of improving oleic oil content and developing pod shatter reduction in Brassica napus (canola, winter oilseed rape) by using gene editing tools on an industrial scaleSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) — Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that its paper on Industrializing Gene Editing in Brassica napus was published in the International Journal of Plant Biology. (Link Article: https://www.mdpi.com/2037-0164/14/4/77) “The ability to scale breeding in a precise and repeatable process is the central breakthrough of our high-speed breeding process, which we refer to as the Trait Machine™ System. Our...

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Catherine Lee, J.D. has been appointed to its Board of Directors. “We are pleased to announce the appointment of Catherine Lee to our Board of Directors,” said Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals. “Cathy brings an extensive track record of accomplishment within the life sciences sector, serving as the General Counsel and Corporate Secretary for multiple companies and advising them on key growth initiatives and strategic transactions. As TFF Pharmaceuticals continues to advance its two clinical programs, Cathy’s...

Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland. Presentation details are summarized below: Title: Discovery of a Novel,...

REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that the first patient has been dosed in Jasper’s phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU called BEACON (a phase 1b/2a Briquilimab dose Escalation trial assessing ACtivity, safety, and pharmacOkinetics iN adult patients with chronic spontaneous urticaria). The BEACON study is evaluating repeat doses of subcutaneous briquilimab...

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Wednesday, December 6, 2023Time: 1:00 p.m. ETLocation: VirtualWebcast Link: Click Here About BioAtla, Inc.BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical...

HOUSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) — via IBN – BlockQuarry Corp. (OTC: BLQC), a leading Texas-based energy and infrastructure company, is excited to share updates on the successful operation of its new Missouri site under the leadership and guidance of Chief Operating Officer (COO) Lawrence Davis, and Company president and chairman Alonzo Pierce.  Since assuming the role of COO, Davis has played a pivotal part in driving the operational vision for BlockQuarry with a laser focus on innovation, speed and growth. One of the most notable milestones achieved is the successful move, reintegration and launch of BlockQuarry’s new self-mining site in Macon, Missouri. “I couldn’t be more proud to say with confidence that BlockQuarry has delivered on its promise, achieving operational status before year-end, thanks to our seamless...

FREMONT, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, announced today that it has started shipping IQ8P™ Microinverters, with a peak output AC power of 480 W, in Mexico to support newer high-powered solar modules. IQ8™ Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher-powered solar modules through increased energy harvesting. IQ8P, the newly available Enphase microinverter, is the most powerful microinverter available from Enphase to-date. The product features a peak output power of 480 W and is designed to seamlessly pair with a full range of solar modules up to 670 W DC. All IQ8...

Society award recognizes Dr. Mallick’s decades of innovative leadership and science advancing the field of computational proteomicsParag Mallick, Ph.D.Co-founder and Chief ScientistSEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of the Gilbert S. Omenn Computational Proteomics Award presented by the US Human Proteome Organization (US HUPO). The award recognizes Dr. Mallick’s career achievements and contributions to bioinformatics analyses and computational methods widely used by the proteomics community. “Developments in computational proteomics enable researchers...